Promising drug targets rare childhood cancers in new trial

NCT ID NCT05918640

Recruiting now Disease control Sponsor: Children's Hospital of Philadelphia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called lurbinectedin in people aged 10 and older whose solid tumors (like Ewing sarcoma) have returned after standard treatment. The goal is to see if the drug is safe and can shrink tumors or delay their growth. Participants must have a specific genetic change called a FET fusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DESMOPLASTIC SMALL ROUND CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood malignant neoplasm desmoplastic small round cell tumor Ewing sarcoma neoplasm undifferentiated (embryonal) sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DESMOPLASTIC SMALL ROUND CELL TUMOR EWING SARCOMA PEDIATRIC CANCER UNDIFFERENTIATED SARCOMA

Contacts and locations

Show contact details

Locations

Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact Email: •••••@•••••
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
University of Iowa Hospitals and Clinics
RECRUITING

Iowa City, Iowa, 52242, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.